cyrilzakka/clinical-trials huggingface dataset:
Application of Different Techniques of Elastic Bandage

This study will be featured as a randomized controlled. As the dependent variable, was considered isometric grip manual force. As independent variable, the presence or absence of forearm bandage in the fist flexor region of the volunteers.

This study is directed to the population of students at the University of Mogi das Cruzes (UMC), and will take part of this study forty volunteers, twenty men and twenty women, aged from eighteen and thirty-eight years old. Will be selected and included volunteers who do not do physical professional activity with upper members, which have no symptom of pain skeletal muscle in the upper members, which have not undergone any type of surgery in the region of the forearm and hand of both members. Will be excluded the volunteers who have injuries, joint injuries, neuromuscular disorder or those who have knowledge of own vestibular or neurological changes. Will also be excluded from study volunteers who do not agree to participate after reading and understanding of informed consent in accordance with resolution 466/12 of the National Ethics Committee and Research. The data acquisition interface will be acquired by an electromyography e a standard of strentgh will maintened in forty Newtons assured by an electronic dynamometer for tests of palmar prehension without and with bandages. The volunteers will not know what kind of intervention will pass. After each application before testing, their both forearms will be covered with a protection. The researcher and the volunteers will not know the tests order.

Eligibility Criteria:
Inclusion Criteria:

* Who do not do physical professional activity with upper members;
* Who have no symptom of pain skeletal muscle in the upper members;
* Who have not undergone any type of surgery in the region of the forearm and hand of both members;
* Consent form signed by the volunteer.

Exclusion Criteria:

* Having less than 18 years old;
* Having more than 38 years old;
* To present some compromise skeletal muscle in the upper members;
* Who do not want take part in the research;
* Who do not signed consent form as volunteer.
Use of Artificial Intelligence Cardiac Ultrasound Technology in Teaching Point of Care Cardiac Ultrasound

The aim of the study is to evaluate the effectiveness of artificial intelligence (A.I.) cardiac ultrasound technology in teaching point of care cardiac ultrasound (POCUS Cardiac).


Eligibility Criteria:
Inclusion Criteria:

* Medical students with no prior training in point of care cardiac ultrasound

Exclusion Criteria:

* Medical students who have received prior training in point of care cardiac ultrasound
* Participants who are unable to complete the entire training programme (pre-training MCQ, simulation session, post-training MCQ, practical evaluation, follow up practical evaluation one month later)
IL-6, IL-12, IL-15 and IL-23 Expression Levels in Rheumatoid Arthritis Patients

Rheumatoid Arthritis (RA) is a systemic autoimmune disease characterized by chronic inflammation and articular damage.

Continuous medical research has dramatically improved the outcomes for patients with RA. Traditional therapeutic approaches have relied on glucocorticoids, nonsteroidal anti-inflammatory drugs (NSAIDs) and disease modifying antirheumatic drugs (DMARDs) such as methotrexate, sulfasalazine or leflunomide. Glucocorticoids and NSAIDs interfere with the inflammatory cascades while DMARDs impede both the inflammatory and the destructive processes of RA.

These drugs, although efficient, are not specifically directed against inflammatory cells or cytokines and are associated with significant toxicity. The development of biologic DMARDs (bDMARDs), has been an important step forward. Their ability to neutralize specific cytokines or target distinct immune cells filled a gap in existing treatment options for RA. \[3\]. However, some patients still have only partial or no response to bDMARDs. More recently, a group of drugs has been developed that inhibit the janus kinase (JAK) family of intracellular tyrosine kinases, which transmit cytokine- mediated signals via the JAK-signal transducer and activator of transcription (STAT) pathway \[4\]. Baricitinib, with a selectivity to inhibit JAK1 and 2, has been FDA approved for RA in 2018 \[5\].

Many cytokines such IL-6, IL-12, IL-15, IL-23, (GM-CSF) and (IFNs) are associated with the pathogenesis of RA. These cytokines transduce signals via the JAK-STAT pathway.


Eligibility Criteria:
Inclusion Criteria:

* Age is at leasr18 years old,
* established RA diagnosis according to 2010 the American College of Rheumatology/European League against Rheumatism classification criteria

Exclusion Criteria:

* Associated autoimmune diseases,
* connective tissue diseases,
* chronic liver or kidney diseases or
* genetic diseases
Surgery Versus Manual Rupture for Dorsal Carpal Ganglion

This study objectives are to compare the efficacy and safety between surgical excision and manual rupture for dorsal carpal ganglion.The participants with dorsal carpal ganglion will be randomized into 2 groups:surgical excision or manual rupture.The patients will be follow-up for at least 1 yr.Telephone interview will be used for outcome assessment.


Eligibility Criteria:
Inclusion Criteria:

* patients with dorsal carpal ganglion

Exclusion Criteria:

* underlying rheumatic condition
* bleeding tendency
Study to Assess Dasatinib in Patients With Core Binding Factors Acute Myelogenous Leukemia

In patients with Core Binding Factors Acute Myelogenous Leukemia, the level of Minimal Residual Disease after chemotherapy is predictive of relapse. The relapse risk is also increased in case of mutations of receptors tyrosine kinase. For patients with a high Minimal Residual Disease level at the end of consolidation or in molecular relapse, maintenance by the inhibitor dasatinib is proposed.


Eligibility Criteria:
Inclusion Criteria:

* Patient presenting de novo or secondary Core Binding Factors Acute Myelogenous Leukemia
* Patient in first and presenting one of following criteria:
* "Resistant" Patient: decrease of less than 3 log of the Acute Myelogenous Leukemia transcript level in the bone marrow after 2 consolidations
* Patient in " molecular relapse ": increase of of more than 1 log of the Core Acute Myelogenous Leukemia transcript level on two successive marrow samples

Exclusion Criteria:

* Woman of childbearing potential
* Concurrent incurable malignacy other than Acute Myelogenous Leukemia
Predictability of Thromboelastography Parameters in Severe Post Partum Hemorrhage

The aim of the study is to determine if thromboelastography parameters can be predictive of severe post partum hemorrhage.


Eligibility Criteria:
Inclusion Criteria:

* Women presenting with a post partum hemorrhage
* needing sulprostone infusion
* during third trimester of pregnancy

Exclusion Criteria:

* known coagulation disorders
Post Market Clinical Follow Up Study to Collect Additional Data and Imaging

The intended use of the PicoSure device with focus lens array used in this study is to assess images to support additional marketing claims for the treatment of pigmentation and mild to moderate wrinkles.

Up to 10 subjects will be enrolled at 1 study center. Subjects will attend a screening/pretreatment visit which may be performed on the same day as the treatment visit. Subjects may receive up to 4 treatments on the face with the PicoSure device.

Eligibility Criteria:
Inclusion Criteria:

* A healthy male or female 18 - 65 years of age.
* Willing to undergo treatments for pigmentation and/or mild to moderate wrinkles on the face with the PicoSure device.
* Understands and accepts obligation not to receive any other procedures on the treatment area through the length of the study.
* Understands and accepts the obligation and is logistically able to be present for all visits.
* Is willing to comply with all requirements of the study and sign the informed consent document.

Exclusion Criteria:

* Is pregnant or of childbearing potential and not using medically effective birth control, or has been pregnant in the last 3 months, currently breast feeding or planning a pregnancy during the study.
* The subject is hypersensitive to light in the near infrared wavelength region.
* The subject takes medication which is known to increase sensitivity to sunlight.
* The subject has seizure disorders triggered by light.
* The subject takes or has taken oral isotretinoin, such as Accutane®, within the last six months.
* The subject has an active localized or systemic infection, or an open wound in area being treated.
* The subject has a significant systemic illness, such as lupus, or an illness localized in area being treated.
* The subject has common acquired nevi that are predisposed to the development of malignant melanoma.
* The subject has herpes simplex in the area being treated.
* The subject is receiving or has received gold therapy.
* The subject is currently enrolled in an investigational drug or device trial, or has received an investigational drug or been treated with an investigational device within in the area to be treated 6 months to entering this study.
* The subject has any condition or is in a situation which in the investigators opinion may put the subject at significant risk, may confound study results or may interfere significantly with the subject's participation.
Gabapentin in Treatment of Muscle Cramps in Patients With Liver Cirrhosis

* Muscle cramps markedly affect the quality of life in cirrhotic patients with no highly effective drug.
* Quinine was suggested for treatment of patients with muscle cramps in patients with liver cirrhosis. However, thrombocytopenia, cardiac arrhythmias and cinchonism are serious side effects.

• The aim of the study was to assess the efficacy and safety of Gabapentin in the treatment of muscle cramps in patients with liver cirrhosis.

Eligibility Criteria:
Inclusion Criteria:

* liver cirrhosis patients

Exclusion Criteria:

* allergy to gapabentin.
* pregnancy and lactation. Renal failure.
MyHand: An Active Hand Orthosis for Stroke Patients

This study seeks to explore the efficacy of several control mechanisms for the device and the impact of a device training program on its utility as a neuroprosthetic and training tool for upper limb recovery.

Hand rehabilitation through occupational therapy is critical for many stroke survivors, but it is also greatly limited by insurance coverage, shortage of therapists, and logistic constraints. To address this, stroke patients need a rehabilitation method they can use on their own, without direct clinical supervision, and for activities of daily living. MyHand is a wearable and active hand orthosis consisting of a glove and forearm splint, equipped with actuators and tendons which connect to the fingers.

Eligibility Criteria:
Inclusion Criteria:

* Subjects over 18 years of age
* History of stroke resulting in significant upper limb impairment
* Full passive range of motion
* Gross control of the proximal upper extremity
* Lacks timely grasp/release
* No more than moderate flexor tone
* Intact cognition

Exclusion criteria include:

* Other Neurological/orthopedic disorders
* Excessive spasticity/contracture
Comprehensive Immune-landscape in Localized Colorectal Cancer

Surgery still remains the mainstay of treatment for localized colorectal cancer. However, nearly 30% of patients with localized colorectal cancer (stage II and stage III) will present with recurrence. Tumor progression is mediated by both intrinsic genetic changes and by extrinsic epigenetic and host environmental factors, including interactions with the immune system. Several studies demonstrated that tumor infiltrating memory T-cells and type, density and location of infiltrating T cells are better predictors of disease-free survival in patients with CRC compared to the standard TNM staging. These data suggest that tumor invasion and progression are more accurately predicted by immune response in the primary tumor. In addition, mismatch repair (MMR)-deficient tumors are characterized a priori by a higher frequency of tumor infiltrating lymphocytes and are associated with significantly improved prognosis. Recently, Stotz et al showed that the preoperative lymphocyte to monocyte ratio in peripheral blood samples predicts clinical outcome in patients with stage III colon cancer. So far there is no comprehensive analysis of the immune-landscape in CRC.

The aim of the current project is to identify a comprehensive panel of immunomarkers in localized colorectal cancer (stage II and stage III) applicable for the detection of patients at high risk of recurrence. For the first time, specific tumor-infiltrating immune cells, mismatch repair protein expression in tumor tissue and preoperative blood based inflammatory markers from routine blood counts in corresponding peripheral blood samples and known clinicopathological features will be correlated with outcome in 300 localized CRC patients.


Eligibility Criteria:
Inclusion Criteria:

* Male and Female patients ≥ 18 years of age;
* Formalin fixed paraffin embedded (FFPE) tissue samples of stage II and stage III colorectal cancer patients consecutively enrolled at the Division of Clinical Oncology, Department of Med.University of Graz (Graz, Austria) between 1995 - 2011

Exclusion Criteria:

* Male and Female patients \< 18 years of age
A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of TD-1211 in Subjects With Opioid-Induced Constipation

A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of TD-1211 in Subjects with Opioid-Induced Constipation


Eligibility Criteria:
Inclusion Criteria:

* History of constipation with onset after initiation of opioid therapy
* Self-reported OIC of approximately 3 spontaneous bowel movements (SBMs) per week or less for each week over at least the previous two week period
* Have used chronic opioids with a total daily dose ≥30 mg of morphine equivalent units (MEU, Appendix 7) for the 12 weeks preceding the Screening Visit. Subjects should have used a stable daily regimen of opioids for at least the 2 weeks preceding the Screening Visit
* Willing to stop all laxatives and other bowel regimens with the exception of bisacodyl/enema treatment allowed per protocol throughout the OIC confirmation, treatment, and follow-up periods

Exclusion Criteria:

* Have participated in a clinical trial of an investigational drug or medical device within 30 days prior to Screening
* Have any condition that may affect drug absorption, (e.g., previous GI surgery)
* Any other condition which, in the opinion of the investigator, could confound or interfere with evaluation of safety or tolerability of the investigational drug, or prevent compliance with the study protocol
The SENTRY Study: Testing Whether Changes in Platelet RNA Enhance the Early Diagnosis of Ovarian Cancer

The purpose of the SENTRY (Stability Enhanced Transcriptional Analytics) Study is to test whether combining a unique analytical approach with changes in platelet RNA expression accurately diagnoses ovarian cancer. Using retrospective data, the investigators have developed an approach that appears to accurately classify ovarian cancer with relatively high sensitivity and specificity. The SENTRY Study will build upon these retrospective analyses to prospectively recruit women with ovarian cancer or an ovarian mass (and healthy control women), obtain platelet RNA samples from whole blood, and perform validation analyses to test our hypothesis.


Eligibility Criteria:
Study Population 1: Women with a Recent Diagnosis of Ovarian Cancer (n=90)

Inclusion Criteria:

1. Women aged 21 years or older
2. Diagnosed with any stage or type of ovarian cancer within the last 8 weeks

Exclusion Criteria:

1. Any other active malignancy
2. Other diagnosis of any cancer within the last 6 months
3. Treatment for any cancer within the last 6 months
4. History of ovarian cancer at any time
5. Currently receiving chemotherapy for ovarian cancer
6. Has already undergone complete ovarian mass resection
7. Unable to provide blood sample

Study Population 2: Control Women without Ovarian Cancer (n=30)

Inclusion Criteria:

1. Women aged 21 years or older

Exclusion Criteria:

1. Any active malignancy or diagnosis of cancer within the last 6 months
2. Treatment for any cancer within the last 6 months
3. Hospitalization or surgery (other than minor surgery such as mole removal) within the last 8 weeks
4. Renal failure (defined as eGFR \< 60 mL/min/1.73m² or on dialysis)
5. Liver failure (defined as having hepatic encephalopathy of any degree, OR moderately severe coagulopathy defined as INR ≥ 1.5, OR known cirrhosis, OR ALT of ≥ 10X ULN, OR total bilirubin of ≥ 3.0 mg/dL, OR diagnosis of liver failure)
6. Decompensated or end-stage heart failure (defined as ACC/AHA Stage C or Stage D heart failure)
7. Poorly controlled diabetes mellitus (defined as a HbA1c \> 9.0%)
8. Venous thrombosis, myocardial infarction, or stroke within the last 8 weeks
9. Currently pregnant or have been pregnant within the last 12 weeks
10. Any blood product transfusion within the last 8 weeks
11. Personal history of ovarian cancer at any time
12. History of bilateral salpingo-oophorectomy
13. History of oophorectomy
14. Unable to provide blood sample

Study Population 3: Women with a Recent Diagnosis of Ovarian Mass (n=125)

Inclusion Criteria:

1. Women aged 21 years or older
2. Diagnosed with any type of ovarian mass within the last 8 weeks

Exclusion Criteria:

1. Any diagnosis of active malignancy
2. Any diagnosis of any cancer within the last 6 months
3. Treatment for any cancer within the last 6 months
4. History of ovarian cancer at any time
5. Currently receiving chemotherapy for ovarian cancer
6. Has already undergone complete ovarian mass resection
7. Unable to provide blood sample
The HIV Functional Cure Potential of UB-421 in ART Stabilized HIV-1 Patients

This is a Phase II, randomized, open-label, multi-center, active-controlled study to assess the safety, tolerability, and efficacy of UB-421 administered as an add-on to the standard ART in ART-treated HIV-1 subjects with stably suppressed HIV-1 plasma VL. The study will be conducted at multiple study centers, designated AIDS hospitals in China.


Eligibility Criteria:
Inclusion Criteria:

1. HIV-1 sero-positive
2. Male with body weight ≥ 50 kg or female with body weight ≥ 45 kg.
3. HIV-1 plasma RNA level below 50 RNA copies/mL.

Exclusion Criteria:

1. Subjects with active systemic infections, except for HIV-1, that the Investigator feels the infections may confound evaluation and treatment for HIV-1.
2. Current active hepatitis B carriers, ie, hepatitis B surface antigen positive.
3. Current active hepatitis C carriers, ie, hepatitis C virus (HCV) antibody positive.
4. History of anaphylaxis to other mAbs.
5. Any vaccination within 8 weeks prior to the first dose of assigned drug.
6. Use of immunomodulators, HIV vaccine, or systemic chemotherapy within 180 days prior to the first dose of assigned drug.
7. Females who are pregnant, lactating, or breastfeeding, or who plan to become pregnant during the study.
Single and Multiple Dose Escalation and Two-sequence Crossover Study of ONO-9054 in Patients With Ocular Hypertension or Mild Open-angle Glaucoma

The primary objective of this study is to evaluate the safety and tolerability of 3 planned doses of ONO-9054 in the eyes of adult male and female patients with ocular hypertension (OHT) or mild open angle-glaucoma (OAG).

The secondary objectives are to evaluate Pharmacodynamics (PD) and to characterize the pharmacokinetic (PK) profile of ONO-9054 and its metabolite in plasma and to compare its tolerability following morning and evening dosing.


Eligibility Criteria:
Inclusion Criteria:

* Male or female subjects age 18-80 (inclusive) with confirmed diagnosis of OHT or OAG
* Confirmed diagnosis of bilateral OHT or chronic open-angle glaucoma
* Able to undergo washout of all ocular drugs
* An IOP ≥ 22mmHg at 8:00 AM and ≥ 21 mmHg at 10:00 AM in at least one eye; but ≤ 35 mmHg at all time points in both eyes on Day -2 and Day -1
* Central corneal thickness 500-600 µm at screening in both eyes
* BCVA 20/100 or better in both eyes

Exclusion Criteria:

* Any history of severe ocular trauma in either eye at any time
* Any history of previous intraocular or ocular laser surgery within the past 3 months or any refractive surgery procedure within the past 6 months of screening visit in the study eye(s)
* Cataracts that prevent observation of the fundus in either eye
Benefits of VILPA in Young Adults

The goal of this clinicaltrial is to assess and compare isokinetic performance, surface electromyography, laboratory parameters, and cardiorespiratory function both before and after engaging in vigorous intermittent lifestyle physical activity(VILPA) within a healthy population.

The main question it aims to answer is:

\[1\] Does VILPA yield effective outcomes? Throughout the course of the trial, participants will engage in a simulated regimen of vigorous intermittent lifestyle physical activity for a duration of 8 weeks. The efficacy of the exercise protocol will be quantified and evaluated through the utilization of a wearable device.


Eligibility Criteria:
Inclusion Criteria:

* Healthy Adults
* No exercise habits (more than 3 months)

Exclusion Criteria:

* Exercising ≥ 3 times per week;
* the presence of chronic diseases, such as hypertension, hyperglycemic states, etc;
* have conducted an exercise program in the past three months.
Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)

The study will evaluate the efficacy and safety of Dotarem enhanced MRA in patients suffering from carotid or vertebral arterial disease.

Each subject will undergo a Time Of Flight (TOF) Magnetic Resonance Angiography (MRA) followed by a Dotarem enhanced MRA.

Eligibility Criteria:
Inclusion Criteria:

* Male or female, aged more than 18 years
* Strongly suspected of having carotid or vertebral arterial disease
* Scheduled (or to be scheduled) to undergo computed tomography angiography (CTA) examination

Exclusion Criteria:

* Known grade IV or V chronic kidney disease (GFR\<30 mL/min/1.73m²)
* Contraindication to MRI
* Acute renal dysfunction within the 6 months preceding Dotarem®-enhanced MRA examination